Gyre Therapeutics Inc. (GYRE) — Cash Flow Reinvestment Rate

Latest as of March 2026: 0.96x

Gyre Therapeutics Inc. (GYRE) has a Cash Flow Reinvestment Rate of 0.96x as of March 2026, reinvesting $3.06 Million (capex $178.00K plus investments $-2.88 Million) from operating cash flow of $3.18 Million. Check earnings quality score of Gyre Therapeutics Inc. to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.96x
(Capex + Investments) / Operating CF

Total Reinvested

$3.06 Million
Capex + Investments

Operating Cash Flow

$3.18 Million
USD

Capital Expenditures

$178.00K
USD

Gyre Therapeutics Inc. Cash Flow Reinvestment Rate (2007–2025)

Historical reinvestment intensity for Gyre Therapeutics Inc. across 5 annual periods. Explore GYRE long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Gyre Therapeutics Inc. (2007–2025)

Year-by-year capital reinvestment analysis for Gyre Therapeutics Inc.. For live market cap and broader valuation context, see Gyre Therapeutics Inc. market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 2.58x $2.61 Million $1.01 Million $1.19 Million ▲ +136.0%
2023 1.09x $28.35 Million $25.89 Million $8.59 Million ▼ -37.9%
2022 1.76x $18.81 Million $10.68 Million $5.00 Million ▲ +7259.4%
2010 0.02x $3.31 Million $138.30 Million $3.31 Million ▼ -88.0%
2007 0.20x $4.94 Million $24.84 Million $4.94 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow